RESUMEN
ABSTRACT: Mpox, previously referred to as monkeypox, was recently deemed a public health emergency in 2022. Our understanding of potential secondary cutaneous manifestations in the setting of this infection is still evolving. We report a rare case of a man who presented with erythematous, painful subcutaneous nodules on his extremities in the setting of recent mpox infection. Biopsy of a lesion from the lower legs revealed a lobular panniculitis with lupus panniculitis-like features on pathology. He was ultimately diagnosed with a unique case of reactive panniculitis secondary to mpox.
Asunto(s)
Enfermedades Autoinmunes , Liquen Escleroso y Atrófico , Humanos , Estudios Retrospectivos , Femenino , Enfermedades Autoinmunes/epidemiología , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/inmunología , Liquen Escleroso y Atrófico/epidemiología , Liquen Escleroso y Atrófico/complicaciones , Liquen Escleroso y Atrófico/inmunología , Masculino , Persona de Mediana Edad , Adulto , AncianoAsunto(s)
COVID-19 , Humanos , COVID-19/complicaciones , COVID-19/diagnóstico , COVID-19/epidemiología , Estudios Retrospectivos , Femenino , Masculino , Persona de Mediana Edad , Anciano , Inmunoglobulina A/sangre , SARS-CoV-2/inmunología , Adulto , Vasculitis por IgA/diagnóstico , Vasculitis por IgA/complicaciones , Vasculitis por IgA/epidemiología , Vasculitis/diagnóstico , Vasculitis/virologíaRESUMEN
Keloids and hypertrophic scars negatively impact the quality of life for millions of people in the world. Unfortunately, though many thera-peutic approaches are used to treat scars, they are often limited in efficacy with high rates of recurrence. Lately, a better understanding of the immune dysregulation of several dermatologic conditions has led to the emergence of multiple cytokine-targeted therapies for numerous conditions. Several studies have implicated T helper 2 (Th2) immune dysregulation in the development of scars and keloids, with interleukins (IL)-4 and -13 identified as pro-fibrotic mediators. Dupilumab is an IL-4 receptor alpha antagonist that inhibits the ex-pression of both IL-4 and -13. Herein, we describe a 44-year-old woman who developed numerous disfiguring hypertrophic scars and keloids after suffering from a severe herpes zoster infection. Given the number of scars, intralesional corticosteroid injections were not feasible. Therefore, treatment with systemic dupilumab was initiated. Many scars flattened, several even developing a cigarette-paper-like texture due to rapid involution. The largest and most recalcitrant keloid was further treated with intralesional dupliumab injec-tions every 2 weeks with an even more dramatic improvement noted in 2 months. To our knowledge, this is the first report of treating multiple keloids and hypertrophic scars with both systemic and intralesional dupilumab. Dermatologists may want to consider treating keloids that cover a large area with systemic dupilumab, a therapy with an established, reassuring safety profile. The most recalcitrant areas may further benefit from concentrating dupilumab by intralesional delivery. J Drugs Dermatol. 2023;22(12):1220-1222. doi:10.36849/JDD.6385.
Asunto(s)
Cicatriz Hipertrófica , Queloide , Femenino , Humanos , Adulto , Queloide/patología , Cicatriz Hipertrófica/tratamiento farmacológico , Calidad de Vida , Anticuerpos Monoclonales Humanizados/uso terapéutico , Inyecciones Intralesiones , Resultado del TratamientoRESUMEN
This case series evaluates hyaluronidase for oral microstomia in a cohort of patients with autoimmune sclerosing disease.